Avatrombopag for platelet engraftment after allogeneic hematopoietic stem cell transplantation in children: a retrospective clinical study.
- Author:
Xin WANG
1
;
Yuan-Yuan REN
1
;
Xia CHEN
1
;
Chao-Qian JIANG
1
;
Ran-Ran ZHANG
1
;
Xiao-Yan ZHANG
1
;
Li-Peng LIU
1
;
Yu-Mei CHEN
1
;
Li ZHANG
1
;
Yao ZOU
1
;
Fang LIU
1
;
Xiao-Juan CHEN
1
;
Wen-Yu YANG
1
;
Xiao-Fan ZHU
1
;
Ye GUO
1
Author Information
- Publication Type:Journal Article
- Keywords: Avatrombopag; Child; Hematopoietic stem cell transplantation; Platelet engraftment; Recombinant human thrombopoietin
- MeSH: Humans; Retrospective Studies; Hematopoietic Stem Cell Transplantation/adverse effects*; Male; Female; Child; Child, Preschool; Infant; Adolescent; Transplantation, Homologous; Blood Platelets/drug effects*; Thiazoles/therapeutic use*; Thrombopoietin/therapeutic use*; Thiophenes
- From: Chinese Journal of Contemporary Pediatrics 2025;27(10):1233-1239
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To evaluate the efficacy and safety of avatrombopag in promoting platelet engraftment after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children, compared with recombinant human thrombopoietin (rhTPO).
METHODS:A retrospective analysis was conducted on 53 pediatric patients who underwent allo-HSCT at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences from April 2023 to August 2024. Based on medications used during the periengraftment period, patients were divided into two groups: the avatrombopag group (n=15) and the rhTPO group (n=38).
RESULTS:At days 14, 30, and 60 post-transplant, platelet engraftment was achieved in 20% (3/15), 60% (9/15), and 93% (14/15) of patients in the avatrombopag group, and in 39% (15/38), 82% (31/38), and 97% (37/38) in the rhTPO group, respectively. There were no significant differences between the two groups in platelet engraftment rates at each time point, cumulative incidence of platelet engraftment, overall survival, and relapse-free survival (all P>0.05). Multivariable Cox proportional hazards analysis indicated that acute graft-versus-host disease was an independent risk factor for delayed platelet engraftment (P=0.043).
CONCLUSIONS:In children undergoing allo-HSCT, avatrombopag effectively promotes platelet engraftment, with efficacy and safety comparable to rhTPO, and represents a viable therapeutic option.
